New data from the combined RESIST studies (RESIST-1 and RESIST-2) show that Aptivus (tipranavir), used with Norvir (ritonavir), provides a superior and durable treatment response for up to three years in treatment-experienced HIV patients versus a comparator group of protease inhibitors.(1) The research was presented at the 11th European AIDS Conference (EACS) in Madrid, Spain.
At 156 weeks, Aptivus combined with ritonavir (Aptivus/r), continues to outperform a group of ritonavir-boosted comparator protease inhibitors that includes low dose ritonavir boosted lopinavir, amprenavir, saquinavir and indinavir. When compared to these protease inhibitors, through three years of therapy, treatment response rates were almost three times higher in the Aptivus/r arm compared to the comparator arm (20.9% vs. 7.5%).
Moreover, patients taking Aptivus/r combined with first-time use of enfuvirtide achieved four-fold greater treatment response rates than patients with comparator protease inhibitors (37.9% vs. 8.2%). In this group, the proportion of patients who achieved a viral load of less than 50 copies/mL at week 156 was more than twice as high with Aptivus/r as with comparator protease inhibitors (21.8% vs. 9.3%).
The new data show that for patients who achieve successful HIV suppression with tipranavir, the results are usually maintained over the long term. In a patient population for which treatment options are limited, this is an important achievement, said lead author Charles Hicks, associate professor of medicine at Duke University, USA.
The adverse event profile for Aptivus/r was comparable with what has been reported in previous analysis. The patient exposure years (PEY)-adjusted adverse event profile was similar between Aptivus and the comparator protease inhibitors group.
At 156 weeks, Aptivus combined with ritonavir (Aptivus/r), continues to outperform a group of ritonavir-boosted comparator protease inhibitors that includes low dose ritonavir boosted lopinavir, amprenavir, saquinavir and indinavir. When compared to these protease inhibitors, through three years of therapy, treatment response rates were almost three times higher in the Aptivus/r arm compared to the comparator arm (20.9% vs. 7.5%).
Moreover, patients taking Aptivus/r combined with first-time use of enfuvirtide achieved four-fold greater treatment response rates than patients with comparator protease inhibitors (37.9% vs. 8.2%). In this group, the proportion of patients who achieved a viral load of less than 50 copies/mL at week 156 was more than twice as high with Aptivus/r as with comparator protease inhibitors (21.8% vs. 9.3%).
The new data show that for patients who achieve successful HIV suppression with tipranavir, the results are usually maintained over the long term. In a patient population for which treatment options are limited, this is an important achievement, said lead author Charles Hicks, associate professor of medicine at Duke University, USA.
The adverse event profile for Aptivus/r was comparable with what has been reported in previous analysis. The patient exposure years (PEY)-adjusted adverse event profile was similar between Aptivus and the comparator protease inhibitors group.
Author:
Time:
Tuesday, October 30th, 2007 at 5:35 am
Category:
Comments:
You can leave a response, or trackback from your own site.
RSS:
You can follow any responses to this entry through the RSS 2.0 feed.
Navigation: